Abstract
Acute coronary syndrome is one of the most prevalent cardiovascular diseases. The acute myocardial infarction is one of its kinds which embodies the indication of fibrinolysis. One of the fibrinolytic types mostly used in Iran is Streptokinase (SK). This study aims to study the short-term clinical outcomes after receiving SK.A prospective cohort study was conducted on 54 patients at hospitals affiliated to Isfahan Medical School. After discharging, within 30 days, patients were followed regarding the morality and major adverse cardiac events (MACE) including Re-MI, unstable Angina, Cerebrovascular Accidents (CVA) and doing revascularization. Results were analyzed in both independent samples and Chi-square by statistical t-tests using SPSS software. Out of 54 patients, 25 individuals received SK versus 29 cases who did not receive that. In 30-day follow-up, no CVA or Re-MI was observed. In patients who did not receive SK, despite more deaths (14.2 % vs. 8 %) and MACE (62% vs. 56 %), it was not statistically significant (P>0.05).In the present study, receiving SK did not cause to reduce the rate of mortality and MACE in the time period of 30 days. However, it is suggested that a similar study with a larger size and also follow-up with long-term outcome be conducted.
Keywords
Copyright
© 2014, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.